Novelix Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Novelix Pharmaceuticals has been growing earnings at an average annual rate of 23%, while the Healthcare industry saw earnings growing at 22.8% annually. Revenues have been declining at an average rate of 16.1% per year. Novelix Pharmaceuticals's return on equity is 2.2%, and it has net margins of 1.9%.
Key information
22.95%
Earnings growth rate
22.09%
EPS growth rate
| Healthcare Industry Growth | 29.41% |
| Revenue growth rate | -16.14% |
| Return on equity | 2.23% |
| Net Margin | 1.85% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Novelix Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 108 | 2 | 3 | 0 |
| 30 Sep 24 | 61 | 0 | 3 | 0 |
| 30 Jun 24 | 32 | -2 | 2 | 0 |
| 31 Mar 24 | 45 | 0 | 3 | 0 |
| 30 Jun 23 | 25 | -1 | 2 | 0 |
| 31 Mar 23 | 19 | -1 | 4 | 0 |
| 30 Jun 22 | 59 | -20 | 6 | 0 |
| 31 Mar 22 | 89 | -20 | 6 | 0 |
| 31 Dec 21 | 109 | -38 | 38 | 0 |
| 30 Sep 21 | 121 | -32 | 39 | 0 |
| 30 Jun 21 | 119 | -37 | 10 | 0 |
| 31 Mar 21 | 96 | -38 | 10 | 0 |
| 31 Dec 20 | 99 | -4 | 11 | 0 |
| 30 Sep 20 | 103 | -3 | 11 | 0 |
| 30 Jun 20 | 105 | -3 | 11 | 0 |
| 31 Mar 20 | 108 | -3 | 11 | 0 |
| 31 Dec 19 | 108 | -2 | 11 | 0 |
| 30 Sep 19 | 106 | -2 | 12 | 0 |
| 30 Jun 19 | 105 | -1 | 11 | 0 |
| 31 Mar 19 | 107 | -1 | 11 | 0 |
| 31 Mar 18 | 107 | -3 | 10 | 0 |
| 31 Mar 17 | 94 | 0 | 7 | 0 |
| 31 Dec 16 | 86 | 1 | 8 | 0 |
| 30 Sep 16 | 79 | 0 | 8 | 0 |
| 30 Jun 16 | 73 | 0 | 8 | 0 |
| 31 Mar 16 | 58 | 1 | 7 | 0 |
| 31 Dec 15 | 58 | -1 | 10 | 0 |
| 30 Sep 15 | 59 | -1 | 9 | 0 |
| 30 Jun 15 | 61 | 0 | 4 | 0 |
| 31 Mar 15 | 64 | 1 | 6 | 0 |
| 31 Dec 14 | 64 | 4 | 5 | 0 |
| 30 Sep 14 | 63 | 4 | 5 | 0 |
| 30 Jun 14 | 62 | 4 | 4 | 0 |
Quality Earnings: 536565 has a large one-off gain of ₹365.4K impacting its last 12 months of financial results to 31st December, 2024.
Growing Profit Margin: 536565 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 536565 has become profitable over the past 5 years, growing earnings by 23% per year.
Accelerating Growth: 536565 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 536565 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (30.2%).
Return on Equity
High ROE: 536565's Return on Equity (2.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 12:29 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novelix Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.